ProsTIC at Peter Mac is a world-leader in theranostics.
Theranostic treatment for prostate cancer involves targeting prostate specific membrane antigen (PSMA) on prostate cancer cells – first with a radioactive molecule to reveal the cancer’s spread via a PET scan and then a similar radioactive molecule that kills cancer cells.
Peter Mac has pioneered research globally, performing our first PSMA PET scan in 2014, and our first PSMA therapy in 2015.